Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Neurological conditions

Beta interferons improve survival in people with MS

Research results show that patients with multiple sclerosis who take beta interferons for at least three years have increased survival compared with those who do not.

3D render of neurons in the brain

Source: Shutterstock.com

Individuals with multiple sclerosis who took beta-interferon treatment for at least three years had a 56% reduced risk of death, compared with shorter-duration treatments, research has found

Beta interferons improve survival in patients with relapsing-onset multiple sclerosis (MS) when used for at least three years, research has shown[1].

The study, published in Brain (18 March 2019), used data from Canada and France on 5,989 people with relapsing-remitting MS who were naïve to disease-modifying therapies at study entry. 

During an average of 11 years of follow-up, 32% of people were exposed to beta-interferon for at least six months. Overall, there were 742 deaths due to any cause and, of these 649 were matched with between 1 and 20 controls by country, sex, age, year and disability level at study entry. 

It was found that those who received beta interferons were 32% less likely to die than unexposed individuals. When stratified by duration, those exposed to at least three years’ beta-interferon treatment had a 56% reduced risk of death while shorter exposure durations were not significantly related with survival.

Beta interferons are the most commonly used disease-modifying drugs in MS worldwide, but little is known of their effects on survival, the researchers explained.

“Further work is warranted to assess whether this survival advantage extends to other disease-modifying therapies [for MS] and whether this observed survival advantage results in a measurable improvement in the quality of life lived,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206411

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.